BiomX reports FY2024 results, $12M financing, Phase 2 DFO readout imminent

BiomX Inc.

Phase 2 topline results for BX211 in diabetic foot osteomyelitis expected by end of March 2025.
February 2025 financing raised ~$12M gross proceeds to support BX004 Phase 2b readout in Q1 2026.
Cash and restricted cash $18.0M at Dec 31, 2024; plus $12M raised in Feb 2025; runway into Q1 2026.
FY2024 net loss $17.7M (vs $26.2M); R&D expenses $24.7M; impairments on goodwill, IPR&D, and assets.
Non-dilutive funding from DHA for BX211 totaled $36.8M to date; manufacturing delays for BX004 resolved.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.